The mucin glycoproteins of the gastrointestinal tract are extensively glycosylated, high molecular weight, multi-unit structures which, in the normal epithelium, are secreted by specialised goblet cells, and form a protective gel over the underlying epithelium (Allen, 1983) . Mucin glycoproteins have also been demonstrated to be differentiation-associated or oncofetal antigens in the gastrointestinal tract (Gold & Miller, 1978; Ma et al., 1980; Bara et al., 1980; Hertzog et al., 1991) . Similar abnormalities of mucin glycoprotein expression have also been identified in other epithelial tissues, including the breast (Griffiths et al., 1987) and ovary (Bhattacharya et al., 1982) . As with other oncofoetal antigens, such as cell surface glycoproteins and glycolipids (Hakomori & Kannagi, 1983; Feizi & Childs, 1985) , mucin glycoproteins may prove to be useful markers of neoplastic change and their expression may be related to the growth characteristics of a tumour, its invasiveness, its metastatic potential, or the host response to the tumour (Pihl, 1984) .
In view of the complex structure of mucins, a panel of MAb with different specificities would be ideal reagents for the detection of changes in composition of mucins that occur under an oncogenic stimulus. We have described the production of two MAb to intestinal cancer mucins and the preliminary chemical characterisation of the mucin antigens (Hertzog et al., 1991) . One MAb designated anti-LIMA 2C3 reacted in the normal adult specifically with mucin of the large intestine, yet showed oncofoetal reactivity with the gastric epithelium. In contrast, another MAb designated anti-SIMA 4D3 reacted in the normal adult specifically with mucin of the small intestine, but showed oncofoetal reactivity with both gastric and colorectal epithelium.
The purpose of this study was to use an expanded panel of MAb to SIMA and LIMA to define the characteristics of tumour-associated mucin expression in 100 cases of colorectal cancer. In particular, we have assessed the amount of mucin by semiquantitative immunohistochemistry and by sandwich ELISA, and correlated the resulting data with various clinicopathological indices and with expression of CEA.
Materials and methods
Mucin extraction andfractionation Mucins were extracted from specimens of resected cancers or normal gastrointestinal tract using 4 M guanidine hydrochloride in phosphate buffered saline (PBS), containing the protease inhibitors: 10 mm N-ethyl maleimide, 1 mM benzamidine hydrochloride, and 25 mM EDTA (Hertzog et al., 1991) . Homogenates were centrifuged at 20,000 x g for 20 min, and the supernatants subjected to three cycles of CsCl density gradient centrifugation for purification of mucin fractions. SIMA banded at a mean buoyant density of 1.34 g ml-' (range 1.32 to 1.37 g ml-'), whereas LIMA banded at a mean buoyant density of 1.45 g ml-' (range 1.36-1.59 gml ') (Hertzog et al., 1991) . Each fraction was assayed for protein content (Bradford, 1976) and antigenicity using sandwich ELISA as outlined below.
Preparation of monoclonal antibodies
The production of the anti-SIMA MAb 4D3 and the anti-LIMA 2C3, using as immunogen, a mucin extract from an adenocarcinoma of the colon (designated sample 1946), has been described elsewhere (Hertzog et al., 1991) . Additional MAb were prepared similarly, but using as immunogen a mucin extract from a different adenocarcinoma of the colon (designated sample 3266). An indirect ELISA was used to screen mouse serum samples or hybridoma culture supernatants for mucin-specific antibodies as previously described (Hertzog et al., 1991 (Hertzog et al., 1991) . All MAb were purified using Protein A sepharose affinity chromatography, prior to use in sandwich ELISA. A description of the reference antigen standard (designated 1946) for the 2C3 and 4D3 assays has been outlined elsewhere (Hertzog et al., 1991 The anti-LIMA MAb 2C3 reacted specifically with mucin in the large intestine, with diffuse, strong reactivity with goblet cells and secreted mucin throughout the large intestine. Apical membrane-associated reactivity on the surface, and at the base of the crypt was also observed. At the light microscopic level, it was not possible to discern whether this apical pattern represented definite membrane-associated or intracellular reactivity. MAb 2C3 did not react with mucin in the small intestine, with the exception of restricted reactivity in the terminal ileum. A very similar pattern of large intestine reactivity was observed with MAb 9B5 which reacted more strongly with goblet cells in the upper crypt (Figure la ), but in contrast to MAb 2C3, MAb 9B5 showed restricted or trace reactivity with goblet cells in the proximal small intestine (Table I) . MAb IOB3 reacted with goblet cell and secreted mucin diffusely throughout the large intestine and more strongly with cells in the lower crypt ( Figure lb) ; but, unlike 2C3 or 9B5, IOB3 reacted with mucin throughout the small intestine.
In contrast the three MAb above, the anti-SIMA MAb 4D3 and 4A1 reacted with small intestinal mucin, but not with large intestinal mucin. MAb 4D3 reacted with goblet cell and secreted mucin, diffusely and intensely, throughout the small intestine, whereas MAb 4A1 showed patchy to restricted reactivity with goblet cell mucin in the small intestine. In contrast to MAb 4D3, MAb 4A1 showed apical membrane-associated reactivity with cells in the upper crypt and luminal surface in the colon (Figure lc) .
Notably, there was no observable difference in the intensity or distribution of MAb reactivities between biopsy and autopsy specimens, consistent with previous evidence that mucin antigens were relatively resistant to physicochemical or enzyme degradation. These results validate the use of autopsy samples for studies of mucin antigen distribution in the GI tract.
In contrast to the anti-mucin MAb described above, reactivity with the anti-CEA polyclonal antiserum was virtually absent throughout the normal gastrointestinal tract apart from occasional apical membrane-associated reactivity at the luminal surface of the large intestine. No reactivity with goblet cells or secreted mucin was observed.
(ii) Colorectal carcinoma Sections of 100 cases of colorectal cancers were stained by immunohistochemistry and assessed histologically for reactivity with different tissue and subcellular compartments (Table I) . Each of the five antibodies reacted, with variable intensity, with secreted mucin in glandular lumina and so-called 'mucinous lakes' (Figure 2a ). Additional individual patterns were consistently observed (Figure 2b) , and occasionally reacted with the supranuclear golgi zone (Figure 2c ). MAb IOB3, reactive with normal large and small intestine mucin, reacted strongly with goblet cells when present (Figure 2d ). This pattern was different from that of MAb 2C3 and 9B5, but similar to that observed for the two anti-SIMA MAb (see below). MAb 1OB3 also reacted weakly with carcinoma cell cytoplasm and occasionally with the apical region.
In contrast to the anti-LIMA MAb, the anti-SIMA MAb 4D3 and 4A1 reacted strongly with goblet cell mucin in colorectal cancer. In addition, MAb 4D3 occasionally reacted with the apical region, whereas MAb 4A1 reacted strongly with the apical region of cells and occasionally with the supranuclear golgi zone. Polyclonal anti-CEA antiserum showed strong reactivity with intraluminal material and with the apical membrane, weaker reactivity with the cytoplasm, but no goblet cell reactivity (Figure 3 ). In terms of subcellular reactivities of each MAb, the general trends were thus as follows: intraluminal secreted mucin reacted with each MAb and anti-CEA; goblet cells, when present within the cancer, reacted strongly with either MAb 4D3, 4A1 or IOB3; the apical membrane region reacted with MAb 2C3, 4A1, and 9B5 and anti-CEA; the supranuclear golgi zone reacted mainly with MAb 4A1. Thus, the biosynthetic pathways of goblet-type cancer cells appeared to have undergone an alteration from the normal large intestinal pattern, such that two inappropriate mucin epitopes were detected by MAb 4D3 and 4A1. However, the less differentiated cancer cells contained both of the 2C3-and 9B5-reactive normal colonic mucin epitopes in addition to the atypical 4D3-and 4AI-reactive small intestinal mucin epitopes.
(iii) Perineoplastic mucosa In the sections of 99/100 colorectal carcinomas that were examined, there was a limited amount of non-neoplastic mucosa present. Staining patterns were thus determined for the narrow Transitional Mucosa I (TM-I) zone, the broader Transitional Mucosa II (TM-II) zone, and in morphologically normal mucosa beyond these two zones, which was present in 49 of the 100 cases.
The reactivity patterns of MAb 2C3, 9B5 and IOB3 in morphologically normal mucosa beyond the TM zones were essentially indistinguishable from their patterns in colorectal ..
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mucosa from normal subjects (Figure 4a ). In the TM-I and TM-II zones, as might be anticipated, the goblet cells reacted normally with the anti-LIMA MAb 2C3 and 9B5 but, in addition, there was strong reactivity with columnar cells in the apical and supranuclear golgi regions.
Notably, anti-SIMA MAb 4A1 and 4D3, which do not react with normal colorectal mucin, reacted not only with TM-I and TM-II, but also with the morphologically normal mucosa beyond these zones. In morphologically normal mucosa, MAb 4D3 showed predominantly goblet cell and extracellular mucin reactivity, as observed in the normal small intestine and colorectal cancer. MAb 4A1, similarly to its pattern in the cancer, showed strong apical membrane-associated reactivity and goblet cell reactivity, and in contrast to its pattern in the cancer, strong golgi reactivity (Figure 4b ). Figure 5 , as the frequen reactivity score of 0-6, representing a s staining intensity and distribution.
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In addition to this, 91/100 cases were pos for the anti-SIMA MAb 4A1 and 77/100 fc 91/100 for CEA, all of which were atypical the perineoplastic mucosa, reactivity with M decreased in frequency from TM-I (4A1, 91 TM-II (4A1, 86%; 4D3, 62%) to the adjac 73%; 4D3, 14%) ( Figure 5) . A less fre rapidly diminishing reactivity in the thr zones was also observed with the polyclon; serum, but the intensity of reactivity in Figure 6 . This ELISA and similar ones using the other MAb could reliably detect 2-250 antibody-reactive units per ml. These assays were not affected by concentrations of guanidinium HCI<0.4 M and could therefore be used to assay tissue homogenates prepared in 4 M guanidinium HCI then diluted 1:10. Results of sandwich ELISA of tissue extracts from segments of the normal large intestine and from six specimens of colorectal cancer are shown in Figure 7 . Mucins were subsequently purified from these tissue extracts by cesium chloride (CsCI) gradients, the yield of mucin antigenicity was 80 to 100%, thus accounting for virtually all of the tissue antigenicity. colon  18  100  100  78  89  72  83  Rectum  39  92  87  85  90  77  97  Total  100  95  90  85  91  77 92 aThe differentiation sometimes varied from one part of a cancer to another, so for this parameter, correlation with mucin antigen reactivity was determined for each sample. Several samples were available from about half of the cases. (i) Normal large intestine The anti-LIMA MAb 2C3 and 9B5, as well as MAb IOB3, reacted strongly with mucin in all five segments of the large intestine from the ascending colon to the rectum; whereas the only trace or undetectable reactivity was evident using the anti-SIMA MAb 4A1 and 4D3 (Figure 7) . Thus, for 2C3, the levels ranged from 6,000 to approximately 30,000 2C3-reactive units/g wet weight of tissue, with the highest levels generally found in the sigmoid colon and rectum (left side). As expected, 2C3-reactive LIMA was undetectable in extracts of normal duodenum, jejunum and ileum, <10 units g-' tissue (data not shown).
Mucin reactive with MAb 9B5 was detected at levels usually about 1,000 to 4,000 9B5-reactive units/g tissue (Figure 7 ), but only trace amounts were detected in the small intestine (data not shown). Mucin reactive with MAb IOB3 was also detected at levels ranging from 1,000 to 3,000 units/g' tissue, and in this case, similar levels were also detected in the small intestine (data not shown).
In contrast to this, the anti-SIMA MAb 4A1 showed only traces of reactivity in the large intestine, ranging from 10 to reactive mucins, not normally detected at significant levels in that organ (Figure 7 ). This analysis also demonstrated the heterogeneity of mucins in colorectal cancers. For example, cancer specimens 1, 2 and 4 show strong reactivity with all five MAb, mucin from specimen 3 reacts with 2C3, IOB3 and 4D3, specimen five with only IOB3 and 4D3, and specimen 6 with only 4D3 and 4A1. Levels of 2C3-reactive mucin in colorectal cancer extracts, compared with levels in the normal colon extracts, were increased in two cases (25,000 and 250,000 units -1), decreased in two cases (400 and 3,000 units g-1), and not detected in two cases. Levels of 9B5-reactive mucin were elevated in one sample (20,000 units g-'), within the normal range in two samples (3,300 and 3,9000 units g-), and not detected in three samples. The levels of 1OB3-reactive mucin in the cancer samples were elevated in five to six cases, ranging from 11,000 to 400,000 units g-1, and not detected in one case. Elevated levels of 4D3-reactive mucin were detected in all six cancer samples, ranging from 1,500 to 33,000 units g'. The levels of 4AI-reactive mucin in the cancer samples were elevated in four to six cases at 600 to 20,000 units g-', and not detected in two cases. (Wolf et al., 1989; Abe et al., 1986; Kim et al., 1986; Sakomoto et al., 1986; Schoentag et al., 1987 ). -The reactivity of the mucin antigens is resistant to formalin fixation and paraffin embedding of the tissues. -The two anti-SIMA MAb recognise cancer mucin antigens that are abnormal for the colorectum.
Discussion
As previously discussed, the sensitivity of the 2C3 and 4D3 epitopes to P-elimination, periodate oxidation or neuraminidase (for 4D3 only) suggest that these epitopes contain, or are influenced by carbohydrate moieties (Hertzog et al., 1991) . Further biochemical characterization of the epitopes for all of these MAbs is in progress, but is limited by the availability of native antigen in sufficient quantities. The reactivity of 9B5 or 4A1 with the Golgi zone is suggestive of possibly a peptide or core carbohydrate epitope; preliminary data suggest 4A1 reactivity is periodate sensitive (data unpublished) consistent with a carbohydrate-dependent epitope. Since the genes coding for two intestinal core proteins designated MUC2 and MUC3 have been cloned, (Gum et al., 1989; 1990) it would be interesting to correlate these with SIMA and LIMA, and determine whether atypical SIMA expression in colorectal cancers is the result of altered glycosylation of normal core protein(s), or expression of new core protein(s).
Atypical reactivity of the anti-SIMA MAbs 4D3 and 4A1 in colorectal carcinomas was usually observed with tissue components associated with mucin, namely glandular lumen secretions, mucinous lakes and goblet cells. Thus, even the well differentiated goblet cells, when present in colorectal cancer, produce the abnormal antigen SIMA. In addition, undifferentiated carcinoma cells also contained material reactive with the two anti SIMA MAb, particularly 4A1, in which case staining was observed in the region of the apical membrane. The MAb IOB3, while reactive with both SIMA and LIMA in normal adults, showed a pattern of cellular reactivity in colorectal cancers that was similar to the anti-SIMA MAb, again highlighting the breakdown of normal mucin antigen patterns that occurs in colorectal cancer.
Abnormal SIMA expression was detected in a high proportion of colorectal carcinomas, even those at an early stage of development such as those at stages A and B (89% positive for 4D3, 86% positive for 4A1) and those of small size (<10cm3, 88% positive for 4D3 and 4A1). Thus aberrant SIMA expression may be an early event in colon carcinogenesis and is even present in the potentially premalignant perineoplastic mucosa (see below). The utility of the two anti-SIMA MAb and anti-CEA, all of which react with antigens not normally present in the colon, in the detection of neoplastic change in the colon and rectum, was further enhanced by the findings that these antibodies reacted with a high proportion of cancers, regardless of histological type, differentiation, stage, site, size, age, or sex.
However, despite the lack of an absolute association of mucin antigen reactivity with any single clinicopathological index, some trends did emerge. The anti-SIMA MAb 4D3 showed a tendency for stronger staining associated with a less malignant phenotype, namely carcinoma of stage A/B, smaller size, better differentiation. Both 4D3 and 10B3 positive tumours had a lower lymphocyte infiltrate, a feature previously reported for histologically-defined 'mucinous tumours' (Pihl, 1984) and interpreted as an indication that mucins may 'shield' cancers from the host immune response (Greaves et al., 1980) . Over 90% of colorectal cancers contained mucin reactive with the two anti-LIMA MAb 2C3 and 9B5 in extracellular mucinous lakes or glandular lumen secretions as observed with the anti-SIMA MAb. However, in contrast to the cellular pattern of anti-SIMA reactivity, the two anti-LIMA MAb did not react with goblet cells in colorectal cancers (albeit the site of reactivity in the normal colon), but reacted with undifferentiated carcinoma cells, in the apical membrane region, and less frequently in the Golgi zone. Some undifferentiated carcinoma cells of the majority of colorectal cancers appear, therefore, to be capable of synthesising and secreting normal colonic mucin. Thus, the normal colonic mucin, LIMA is produced in colorectal cancers by atypical cells, possibly goblet cell precursors or intermediate cells (Dawson & Filipe, 1976) but not by goblet cells. In addition to this qualitative abnormality of LIMA production in colorectal cancers, quantitative differences from normal were detected, by ELISA using MAb 2C3 or 9B5, as increased production in some cases and absence in others. The occurrence of LIMA in the cancers showed no trends with any clinicopathological parameters; the anti-LIMA MAb and the anti-SIMA MAb even reacted with a high proportion of colorectal cancers that would have been diagnosed histologically as 'non-mucinous'. These observations may be explained by the reactivity of these MAb frequently with mucin antigens in cellular or tissue compartments not normally associated with mucins.
The atypical subcellular and extracellular distribution of reactivity with these anti-mucin MAb is a reflection of altered glycoprotein biosynthesis and warrants further investigation at the ultrastructural and biochemical level. Altered metabolism may take the form of incomplete synthesis, degradation or synthesis of new (neo-) molecules as proposed for other differentiation-associated glycoconjugates (Hakomori & Kannagi, 1983) . However, mucins differ from other tumour marker antigens, such as those on the cell surface, because they are more extensively glycosylated and are naturally secreted molecules. Mucin production by tumours may therefore be more readily detected in biological fluids, and may have different consequences for tumour progression. Abnormal mucin production may influence the progression of the tumour by affecting processes such as growth or invasion, or by presenting 'unseen' antigens to the host immune system. Furthermore, abnormal mucin glycoprotein metabolism or distribution may be an important factor in determining whether these antigens reach the blood, as proposed for CEA (Hamada et al., 1985) . Indeed, each of these MAb, on occasions, was observed to stain serum in blood vessels in specimens of colorectal cancer, and preliminary studies using ELISA have also detected mucin antigens in blood samples from some patients with colorectal cancer.
Whatever the underlying cause of the altered mucin glycoprotein metabolism in colorectal cancers, it is interesting that it varies in detail from one cancer to the next. Thus, cancers showed different profiles of reactivity with the individual anti-mucin MAb and CEA, evident in both immunohistochemical and ELISA studies. The reactivity of different regions of a cancer specimen were also frequently complementary in nature. Similar 'mosaicism' of reactivity in cancers has been described for another series of related tumour antigens (Nakasaki et al., 1989) . A cocktail of complementary antibodies would therefore react with a higher proportion of cancers and with more cells in a tumour than any of these individual antibodies, and may be the optimal reagent to use for tissue or blood diagnosis, immunolocalisation or tumours, or delivery of immunotoxins.
In the perineoplastic mucosa, the frequency of reactivity with the anti-SIMA MAbs 4D3 and 4A1 decreased only slightly from TM-I to TM-II (70 and 90% to 62 and 86% respectively), compared with the dramatic drop in frequency and intensity of reactivity with CEA (65% in TM-I, and 35% in TM-II). Similarly, abnormal mucin antigen expression detected by one of the anti-SIMA MAbs 4D3 or 4A1 was detected in the morphologically normal mucosa in a high proportion of cases (80%) versus CEA (24%). Clearly, these apparently normal cells are undergoing biochemical change.
It remains an open question as to whether this change is precancerous (Filipe, 1969; Decaens et al., 1983) or reactive (Isaacson & Attwood, 1979; Boland & Kim, 1987) . Future studies will be directed to the factors that may be responsible for such changes, and the extent of these or similar changes in mucosa distant from the tumour.
In conclusion, we have described alterations of mucin production in the majority of colorectal cancers of every stage, differentiation and histological type, size and site. Not only were the new, atypical mucins (SIMA) produced, but the normal colonic mucin (LIMA) was found in abnormal cell types, subcellular and tissue compartments. The broad reactivity of this panel of MAb would be an advantage for their use, perhaps in combination with each other and/or CEA, in immunolocalisation, serological monitoring, or therapy of colorectal cancer.
